Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients

British Journal of Clinical Pharmacology

Volumn 55, Issue 2, 2003, Pages 203-211

  Bauer, Steffen ^a,b   Störmer, Elke ^a   Johne, Andreas ^a   Krüger, Hagen ^a   Budde, Klemens ^a   Neumayer, Hans Hellmut ^a   Roots, Ivar ^a   Mai, Ingrid ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Cyclosporin A; Drug interaction; Metabolism; Patients; Pharmacokinetics; St John's wort

Indexed keywords

ALLOPURINOL; AMLODIPINE; ATENOLOL; BENAZEPRIL; BENZBROMARONE; CELIPROLOL; CERIVASTATIN; CYCLOSPORIN A; DOXAZOSIN; DRUG METABOLITE; FELODIPINE; FUROSEMIDE; HYPERICUM PERFORATUM EXTRACT; LOSARTAN; METHYLPREDNISOLONE; METOPROLOL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NISOLDIPINE; NITRENDIPINE; PIRETANIDE; RANITIDINE; SANDIMMUN OPTORAL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; FEMALE; GRAFT REJECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERICUM PERFORATUM; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; OPEN STUDY; PRIORITY JOURNAL; TIME SERIES ANALYSIS;

EID: 10744232730     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01759.x     Document Type: Article

References (46)

1. Johne A, Brockmöller J, Bauer S et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66: 338-345.
2. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort. Lancet 2000; 355: 547-548.
3. Johne A, Schmider J, Brockmöller J et al. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J Clin Psychopharmacol 2002; 22: 46-54.
4. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant rejection due to Saint John's wort. Lancet 2000; 355: 548-549.
5. Moschella C, Jaber BL. Interaction between cyclosporine and Hypericum perforatum (St. John's wort) after organ transplantation. Am J Kidney Dis 2001; 38: 1105-1107.
6. Karliova M, Treichel U, Malago M et al. Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol 2000; 33: 853-855.
7. Breidenbach T, Hoffmann MW, Becker T, Schlitt H, Klempnauer J. Drug interaction of St John's wort with cyclosporin. Lancet 2000; 355: 1912.
8. Mai I, Krüger H, Budde K et al. Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther 2000; 38: 500-502.
9. Turton-Weeks SM, Barone GW, Gurley BJ et al. St John's wort: a hidden risk for transplant patients. Prog Transplant 2001; 11: 116-120.
10. Gaston RS. Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis 2001; 38: S25-S35.
11. Christians U, Strohmeyer S, Kownatzki R et al. Investigations on the metabolic pathways of cyclosporine. II. Elucidation of the metabolic pathways in vitro by human liver microsomes. Xenobiotica 1991; 21: 1199-1210.
12. Christians U, Sewing KF. Cyclosporin metabolism in transplant patients. Pharmacol Ther 1993; 57: 291-345.
13. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993; 24: 472-495.
14. Combalbert J, Fabre I, Fabre G et al. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989; 17: 197-207.
15. Sewing KF, Christians U, Kohlhaw K et al. Biologic activity of cyclosporine metabolites. Transplant Proc 1990; 22: 1129-1134.
16. Aoyama T, Yamano S, Waxman DJ et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver, cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 1989; 264: 10388-10395.
17. Bouis P, Brouillard JF, Fischer V, Donatsch P, Boelsterli UA. Effect of enzyme induction on Sandimmun (cyclosporin A) biotransformation and hepatotoxicity in cultured rat hepatocytes and in vivo. Biochem Pharmacol 1990; 39: 257-266.
18. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997; 27: 201-214.
19. Lown KS, Mayo RR, Leichtman AB et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62: 248-260.
20. Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol 1996; 118: 1841-1847.
21. Dürr D, Stieger B, Kullak-Ublick GA et al. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68: 598-604.
22. Perloff MD, von Moltke LL, Störmer E, Shader RI, Greenblatt DJ. Saint John's wort. An in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 2001; 134: 1601-1608.
23. Nahrstedt A, Butterweck V. Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry 1997; 30 (Suppl. 2): 129-134.
24. Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Muller WE. Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci 1998; 63: 499-510.
25. Butterweck V, Petereit F, Winterhoff H, Nahrstedt A. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test. Planta Med 1998; 64: 291-294.
26. Moore LB, Goodwin B, Jones SA et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000; 97: 7500-7502.
27. Wentworth JM, Agostini M, Love J, Schwabe JW, Chatterjee VK. St John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000; 166: R11-R16.
28. Christians U, Zimmer KO, Wonigeit K, Maurer G, Sewing KF. Liquid-chromatographic measurement of cyclosporin A and its metabolites in blood, bile, and urine. Clin Chem 1988; 34: 34-39.
29. Mück W, Mai I, Fritsche L et al. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 1999; 65: 251-261.
30. Brockmöller J, Neumayer HH, Wagner K et al. Pharmacokinetic interaction between cyclosporin and diltiazem. Eur J Clin Pharmacol 1990; 38: 237-242.
31. Christians U, Strohmeyer S, Kownatzki R et al. Investigations on the metabolic pathways of cyclosporine. I. Excretion of cyclosporine and its metabolites in human bile - isolation of 12 new cyclosporine metabolites. Xenobiotica 1991; 21: 1185-1198.
32. Maurer G, Lemaire M. Biotransformation and distribution in blood of cyclosporine and its metabolites. Transplant Proc 1986; 18: 25-34.
33. Kwei GY, Alvaro RF, Chen Q et al. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab Dispos 1999; 27: 581-587.
34. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000; 294: 88-95.
35. Kerb R, Brockmöller J, Staffeldt B, Ploch M, Roots I. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 1996; 40: 2087-2093.
36. Bleck JS, Schlitt HJ, Christians U et al. Urinary excretion of cyclosporin and 17 of its metabolites in renal allograft recipients. Pharmacology 1989; 39: 160-164.
37. Wonigeit K, Kohlhaw K, Winkler M, Schaefer O, Pichlmayr R. Cyclosporine monitoring in liver allograft recipients: two distinct patterns of blood level derangement associated with nephrotoxicity. Transplant Proc 1990; 22: 1305-1311.
38. Kohlhaw K, Wonigeit K, Schafer O et al. Association of very high blood levels of cyclosporin metabolites with clinical complications after liver transplantation. Transplant Proc 1989; 21: 2232-2233.
39. Leunissen KM, Beuman GH, Bosman FT, van Hooff JP. The nephrotoxic effects of cyclosporine metabolites. Transplant Proc 1988; 20: 738-739.
40. Kunzendorf U, Brockmöller J, Jochimsen F, Roots I, Offermann G. Activity of cyclosporin metabolites M17 and M1. Transplant Proc 1990; 22: 1697-1699.
41. Rush DN. Cyclosporine toxicity to organs other than the kidney. Clin Biochem 1991; 24: 101-105.
42. Christians U, Sewing KF. Alternative cyclosporine metabolic pathways and toxicity. Clin Biochem 1995; 28: 547-559.
43. Mayer RD, Berman S, Cockett AT, Maines MD. Differential effects of cyclosporin on hepatic and renal heine, cytochrome P-450 and drug metabolism. Possible role in nephrotoxicity of the drug. Biochem Pharmacol 1989; 38: 1001-1007.
44. Copeland KR, Thliveris JA, Yatscoff KW. Toxicity of cyclosporine metabolites. Ther Drug Monit 1990; 12: 525-532.
45. Donatsch P, Rickenbacher U, Ryffel B, Brouillard JF. Sandimmun metabolites: their potential to cause adverse reactions in the rat. Transplant Proc 1990; 22: 1137-1140.
46. Radeke HH, Christians U, Bleck JS, Serving KF, Resch K. Additive and synergistic effects of cyclosporine metabolites on glomerular mesangial cells. Kidney Int 1991; 39: 1255-1266.